Flamingo Therapeutics has initiated a new Investigator-initiated Trial aimed at assessing the safety and effectiveness of danvatirsen in patients with acute myeloid leukemia and myelodysplastic syndrome

Verrica Pharmaceuticals Inc., specializing in dermatology therapeutics, has announced a significant update to its licensing agreement with Torii Pharmaceutical Co. Ltd. This involves collaborating on a global pivotal Phase 3 clinical trial of YCANTH®

Petros Pharmaceuticals, Inc., a company focused on improving access to medication through over-the-counter drug development programs, has announced that all strengths of its prescription erectile dysfunction medication,

AriBio Co., Ltd., a biotechnology company dedicated to leading the treatment of neurodegenerative diseases, announced that the National Medical Products Administration of China, along with the Center for Drug Evaluation

Brii Biosciences Limited, a leading biotechnology company, announced today that the National Medical Products Administration's Center for Drug Evaluation has granted Breakthrough Therapy Designations

PharmaTher Holdings Ltd., a specialty pharmaceutical company, has received an Amendment Acknowledgment Letter from the U.S. Food and Drug Administration for its Priority Original Abbreviated New Drug Application

The Jackson Laboratory, a nonprofit biomedical research organization, has forged a strategic partnership with AbTherx, a biotechnology innovator, to advance antibody discovery and expedite the development of vital new therapies.

Metaphore Biotechnologies, in conjunction with Flagship Pioneering, has announced a significant research collaboration with Novo Nordisk aimed at developing innovative therapeutics for managing obesity.

Neurocrine Biosciences, Inc., has announced the initiation of its Phase 1 clinical trial to evaluate NBI-1076986, a novel compound targeting the M4 subtype-selective muscarinic acetylcholine receptor.

CEL-SCI Corporation has recently shared positive news from its discussion with the U.S. Food and Drug Administration regarding the approval pathway for its cancer immunotherapy, Multikine